A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

NCT05813925 · Completed

Last updated 2026-05-28

This study is testing whether the medication CagriSema helps adults in East Asia who are overweight or have obesity lose weight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 331 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-04 · est. completion 2025-03

Where 28 sites · Japan, Taiwan

What this study is testing ClinicalTrials.gov NCT05813925 ↗

Description as written by the study sponsor.

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

Treatments tested

Cagrilintide Drug

Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Semaglutide Drug

Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Placebo Semaglutide Drug

Participants will receive placebo matched to semaglutide

Main thing measured	Relative Change in Body Weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity or Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05813925 ↗